Reports
Reports
Sale
The global contraceptive devices market attained a value of about USD 11.57 billion in 2023. The market is anticipated to grow further at a CAGR of 6.6% during the forecast period of 2024-2032 to attain a value of USD 20.48 billion by 2032.
Contraceptive Devices Market Size
Contraceptive Devices Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Contraceptive Devices Market Overview
3.1 Global Contraceptive Devices Market Historical Value (2017-2023)
3.2 Global Contraceptive Devices Market Forecast Value (2024-2032)
4 Global Contraceptive Devices Market Landscape
4.1 Global Contraceptive Devices Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Contraceptive Devices Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Distribution Channel
5 Global Contraceptive Devices Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Contraceptive Devices Market Segmentation
6.1 Global Contraceptive Devices Market by Product Type
6.1.1 Market Overview
6.1.2 Male Contraceptive Devices
6.1.2.1 Condoms
6.1.2.2 Spermicides
6.1.3 Female Contraceptive Devices
6.1.3.1 Female Condoms
6.1.3.2 Contraceptive Sponges
6.1.3.3 Contraceptive Vaginal Rings
6.1.3.4 Intrauterine Devices
6.1.3.5 Sub-dermal Contraceptive Implants
6.1.3.6 Non-Surgical Permanent Contraceptive Devices
6.2 Global Contraceptive Devices Market by Technology
6.2.1 Market Overview
6.2.2 Hormonal Contraceptives
6.2.3 Barrier Contraceptives
6.3 Global Contraceptive Devices Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Online Channel
6.3.5 Public Channel
6.3.6 Others
6.4 Global Contraceptive Devices Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Contraceptive Devices Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Contraceptive Devices Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Contraceptive Devices Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Contraceptive Devices Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Contraceptive Devices Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Bayer AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Janssen Global Services, LLC
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Teva Pharmaceutical Industries Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck Sharp & Dohme Corp.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mylan N.V.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Reckitt Benckiser Group plc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Veru Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Medisafe Distribution Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 CooperSurgical, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Devex
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Mayer Laboratories, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Allergan plc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Agile Therapeutics
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 HLL Lifecare
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 ANSELL LTD
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Mankind Pharma
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 TTK HealthCare
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Boehringer Ingelheim International GmbH.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 V-Care Pharma Pvt. Ltd.
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 VARDHAMAN LIFECARE PVT LTD
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
17.22 Cipla Inc.
17.22.1 Financial Analysis
17.22.2 Product Portfolio
17.22.3 Demographic Reach and Achievements
17.22.4 Mergers and Acquisitions
17.22.5 Certifications
18 Global Contraceptive Devices Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global contraceptive devices market is assessed to grow at a CAGR of 6.6% between 2024 and 2032.
The major market drivers are the rising number of unwanted pregnancies, changing lifestyles, and government policies encouraging prevention of unwanted pregnancies.
The key market trends guiding the growth of the market include the increasing disposable incomes, the growing adoption of contraceptive devices, and the surging focus on population management.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The different device types of contraceptive devices include vaginal rings, diaphragms, condoms, cervical caps, sponges, and intra uterine device (IUDs), among others.
The significant end users of contraceptive devices in the market are male and female.
The major distribution channels of contraceptive devices include retail pharmacy, hospital pharmacy, online pharmacy, public channel and NGO, and clinics, among others.
The major players in the market are Janssen Pharmaceutical Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., and Reckitt Benckiser Group PLC, among others.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.